Bioconjugate & ADC Development - Abzena

Bioconjugate & ADC Development

Early de-risking of bioconjugate discovery & development.

Leverage our expertise to de-risk your bioconjugate development, early.

There is no one solution to the development of antibody-drug conjugates (ADCs). Every candidate brings its own set of challenges to the bioconjugate and ADC development process. Abzena can guide you in the development of a matrix of candidates that can be tested to find the ideal bioconjugate or ADC for your patients.

Contact Us

We partner with you to apply the right set of bioassays and analytics to assess the ‘developability’ of your lead candidates. Our comprehensive approach to bioconjugate and ADC development ensures that the candidates you take forward have reduced liabilities and a de-risked development path.

We have worked with hundreds of bioconjugate candidates and have the experience to help inform your approach and reduce project timescales by having a developability approach covering specificity, functionality, safety, and manufacturability.

Overcoming early bioconjugate development challenges

We understand that bioconjugate & ADC development is a balancing act. To mitigate and balance those scales more favorably, it is essential to gather as much information about a bioconjugate candidate early. This means that working together we can make more informed decisions further down the line.

Our full-time equivalent (FTE) model provides you the flexibility to apply the necessary expertise to your project with data guiding the best approach to select the optl lead candidate for progression to cell line development and ADC manufacturing.

Contact Us

Abzena’s team of experts have the decades of experience that can successfully carry your ADC candidate from early discovery through development and beyond.

Contact Us

Integrated end-to-end capabilities

Integrated Bioconjugate & ADC Development Services - Abzena

Our integrated end-to-end capabilities mean our design team can utilize information generated during our developability assessment to remove or reduce any liabilities in real-time and improve the developability profile of your drug, mitigating risks of major issues in the later development phases.

Contact Us

Bioassays

To select your best candidate for clinical development our team ensures that your ADC aligns with your required functional and safety profile by testing in standard, off-the-shelf, or custom-developed bioassays.

We also utilize an extensive range of assays to evaluate:

  • Internalization
  • Trafficking
  • Potency
  • Bystander effects
  • Safety characterization

If your novel ADC and bioconjugate requires customized assays, our team has the know-how and expertise to develop them.

Analytics

Full characterization of your ADC is assessed by standard and orthogonal assays to ensure that your molecule meets the critical parameters to support development, stability, and manufacture.

Additional assays to support the stability and safety assessment will guide the stage-specific selection of ADC candidates through to the final lead selection.

Related Content

Blog: 10 Things to Consider When Developing an ADC

Learn More

Abzena Announces Major Investment in Bioconjugation and ADC Capabilities

Learn More

Bioconjugate & ADC Design

We design and deliver tailored solutions for small molecule intermediates including high potency chemistry, payloads, linkers, payload-linker chemical intermediates, bioconjugation and Antibody Drug Conjugates (ADCs).

Learn More

Let’s move medicine forward.

ADCs and other bioconjugates are rapidly emerging as one of the fastest-growing development areas in biologic anti-cancer treatment. The bioconjugate asset you’re developing right now can make a real difference for human health. Let us apply our expertise to accelerate and maximize its potential.

Contact Us